Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541008 | 0.92 | L3MBTL1 (0.41) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL4718990 | 0.92 | L3MBTL1 (0.43) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL14072845 | 0.92 | L3MBTL1 (0.39) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL4586053 | 0.91 | L3MBTL1 (0.40) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL5538501 | 0.91 | KDM4E (0.43) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL5538510 | 0.90 | GRIN2B (0.43) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL5541014 | 0.90 | L3MBTL1 (0.41) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL5546775 | 0.89 | L3MBTL1 (0.39) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL16991731 | 0.88 | L3MBTL1 (0.41) | L3MBTL1GRIN2BMEN1KMT2ACNR2 | |
| SCHEMBL5540909 | 0.88 | L3MBTL1 (0.41) | L3MBTL1GRIN2BMEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | L3MBTL1 1487/4885GRIN2B 3954/4885MEN1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.